Head-to-head · WeighScore
Beluga Health vs Embody
The verdict
Embody takes it — 76.2/100 to 55.8/100.
Embody grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Embody offers compounded semaglutide and tirzepatide via injection plus a unique compounded oral tirzepatide gum formulation.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Beluga Health | Embody |
|---|---|---|
| WeighScore | 55.8/100 | 76.2/100 |
| Grade | C | C |
| Scorecard rank | #431 | #52 |
| Semaglutide | Not disclosed | $79/mo (all doses, promotional rate, compounded) |
| Tirzepatide | Not disclosed | $129/mo (all doses, promotional rate, compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #431 · C
Strengths
- Supports GLP-1 care with compounded semaglutide and tirzepatide
- Board-certified providers and a 50-state medical infrastructure
- LegitScript certified with SOC 2 and ISO 27001 security
- Pharmacies follow FDA/USP standards with third-party batch testing
- Powers many DTC brands as a turnkey telehealth backbone
Where it loses points
- White-label B2B group, not a direct consumer-facing service
- Offers compounded, not FDA-approved branded, GLP-1s
- No public consumer pricing for the GLP-1 offering
- Cited among nationwide groups tied to FDA telehealth GLP-1 scrutiny
- Care quality varies by the consumer brand using the platform
Graded #52 · C
Strengths
- Among the lowest flat rates in the compounded segment — $79/mo semaglutide and $129/mo tirzepatide injection at every dose
- Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
- Available in all 50 states with no insurance friction
- 24/7 unlimited clinician messaging and dose-adjustment support included
- Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine
Where it loses points
- The $79 flat rate relies on an auto-applied promo 'locked forever' — list price in the terms is $199/mo and reviewers allege the lock isn't honored
- Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
- Pharmacy partners not publicly named — compounding source transparency is limited
- Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.